Try our beta test site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

This study has been completed.
Sponsor:
Collaborator:
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01369225
First received: May 10, 2011
Last updated: January 19, 2017
Last verified: January 2017
  Purpose
This is a study to evaluate the safety and tolerability of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients who complete study B2601001 may participate in this trial and receive AAB-003 (PF-05236812). Each patient's participation will last approximately 52 weeks.

Condition Intervention Phase
Alzheimer's Disease
Drug: AAB-003 (PF-05236812)
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Multicenter, Open-label Extension, Multiple Dose, Parallel Group Study To Investigate The Long-term Safety And Tolerability Of Aab-003 (Pf-05236812) Administered Intravenously In Subjects With Mild To Moderate Alzheimer's Disease Previously Treated With Aab-003 Or Placebo In Protocol B2601001

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Baseline up to Week 52 ]
    An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.

  • Number of Participants With Laboratory Abnormalities Meeting the Criteria for Potential Clinical Concern [ Time Frame: Baseline up to Week 52 ]
    The following laboratory parameters were analyzed: hematology (hemoglobin, hematocrit, red blood cell [RBC] count, RBC morphology, platelet count, white blood cell [WBC] count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (blood urea nitrogen [BUN], creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin, alkaline phosphatase, uric acid, albumin, and total protein; urinalysis (pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, microscopy [if urine dipstick was positive for blood, protein, nitrites or leukocyte esterase]); others (coagulation panel, circulating immune complex, and complement activation).

  • Number of Participants With Potentially Clinically Important Vital Sign Findings [ Time Frame: Baseline up to Week 52 ]
    Vital signs assessment included pulse rate and blood pressure. Criteria for vital sign values meeting potential clinical concern included: supine/sitting pulse rate <40 or >120 beats per minute (bpm); standing pulse rate <40 or >140 bpm; systolic blood pressure (SBP) of more than or equal to (>=)30 millimeters of mercury (mm Hg) change from baseline in same posture or SBP <90 mm Hg, diastolic blood pressure (DBP) >=20 mmHg change from baseline in same posture or DBP <50 mm Hg.

  • Number of Participants With Potentially Clinically Important Electrocardiogram (ECG) Findings [ Time Frame: Baseline up to Week 52 ]
    ECG parameters included PR interval, QRS interval, and QT interval. Criteria for ECG changes meeting potential clinical concern included: PR interval >=300 milliseconds (msec) or >=25% increase when baseline is >200 msec and >=50% increase when baseline is less than or equal to (<=)200 msec; QRS interval >=200 msec or >=50% increase from baseline when baseline is less than or equal to 100 msec and >=25% increase when baseline is >100 msec; and QTcF >=450 msec or >=30 msec increase.

  • Number of Participants With Abnormal Physical Examination Findings [ Time Frame: Baseline up to Week 52 ]
    A full physical examination consisted of an examination of the abdomen, genitourinary and cardiovascular systems, lungs, lymph nodes, mouth, musculoskeletal and neurological systems, skin, extremities, head, ears, eyes, nose, throat and thyroid gland. Criteria for abnormal physical findings was based on the investigator's discretion and any new physical examination findings were documented as AEs. Only sites with at least 1 participant abnormality are reported.

  • Number of Participants With Abnormal Neurological Examination Findings [ Time Frame: Baseline up to Week 52 ]
    Neurological examinations were done to the extent needed to assess the subject for any potential changes in neurological status, as determined by the investigator. Examinations included level of consciousness, speech, cranial nerves, motor, sensory, coordination, gait, and tendon reflexes. Only tests with at least 1 participant abnormality are reported.

  • Number of Participants With Suicidal Ideation or Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) [ Time Frame: Baseline up to Week 52 ]
    The C-SSRS captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. C-SSRS assesses whether participant experienced the following: completed suicide; suicide attempt; preparatory acts towards imminent suicidal behavior; suicidal ideation; self-injurious behavior, no suicidal intent. The results presented are the number of participants with completed suicide or non-fatal suicide events or behaviors. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline.

  • Number of Participants With Any New Magnetic Resonance Imaging (MRI) Findings [ Time Frame: Baseline up to Week 52 ]
    Brain MRIs were collected to assess for potential drug-related changes that might have constituted a safety concern. Findings suggestive of either vasogenic edema or intracranial hemorrhage were to be reported as AEs of special circumstance.


Other Outcome Measures:
  • Number of Participants With Positive Anti-Drug Antibodies (ADA) Titer [ Time Frame: Baseline, Week 52 ]
    Number of participants with positive sample(s) in the ADA assay and in the neutralizing anti-drug antibodies (NAb) assay. An endpoint titer >=6.64 corresponded to positive ADA category value. The number of participants who tested positive on 1 or more occasions is reported.

  • Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Scores at Week 52 [ Time Frame: Baseline, Week 52 ]
    ADAS-Cog is a structured scale that evaluates memory, orientation, attention, reasoning, language and constructional praxis. The ADAS-Cog comprises 11 items that are summed to a total score ranging from 0 to 70, with higher scores indicate greater cognitive impairment.

  • Change From Baseline in Disability Assessment in Dementia (DAD) at Week 52 [ Time Frame: Baseline, Week 52 ]
    The DAD is a functional assessment comprised of 40 items (17 items related to self-care and 23 items involving instrumental activities of daily living). The DAD assessment is scored from 0 to 100; higher scores indicate better function.

  • Change From Baseline in Neuropsychiatric Inventory (NPI) Behavioral Symptoms at Week 52 [ Time Frame: Baseline, Week 52 ]
    The NPI is an instrument used to assess changes of behavior that have appeared in a defined period of time in subjects with Alzheimer's Disease and other dementias. Twelve behavioral areas are assessed: delusions, apathy, hallucinations, disinhibition, agitation, irritability, depression, aberrant motor behavior, anxiety, nighttime behaviors, euphoria, appetite, and eating changes. The NPI score is based on frequency and severity of specific behaviors within these categories. Severity (1=Mild to 3=Severe), frequency (1=occasionally to 4=very frequently) scales recorded for each domain; frequency*severity=each domain score (range 0-12). Total score=sum of each domain score (range 0-144); higher score=greater behavioral disturbances; negative change score from baseline=improvement.

  • Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Scores at Week 52 [ Time Frame: Baseline, Week 52 ]
    The CDR scale is a dementia staging instrument that tracks the progression of cognitive impairment in the following 6 categories: memory, orientation, judgment and problem solving, involvement in community affairs, home and hobbies, and personal care. The CDR-SB scale is obtained by summing the ratings in each of the 6 categories, ranging from 0 to 18. Higher scores indicate greater disease severity.

  • Change From Baseline in Mini-Mental State Exam (MMSE) Scores at Week 52 [ Time Frame: Baseline, Week 52 ]
    The MMSE is a brief 30-point questionnaire test that is used to assess cognition. Scores range from 0 to 30, with higher scores indicating better cognitive state.


Enrollment: 52
Study Start Date: July 2011
Study Completion Date: August 2014
Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 0.5 mg/kg AAB-003 Drug: AAB-003 (PF-05236812)
0.5 mg/kg AAB-003, IV
Experimental: 1 mg/kg AAB-003 Drug: AAB-003 (PF-05236812)
1 mg/kg AAB-003, IV
Experimental: 2 mg/kg AAB-003 Drug: AAB-003 (PF-05236812)
2 mg/kg AAB-003, IV
Experimental: 4 mg/kg AAB-003 Drug: AAB-003 (PF-05236812)
4 mg/kg AAB-003, IV
Experimental: 8 mg/kg AAB-003 Drug: AAB-003 (PF-05236812)
8 mg/kg AAB-003, IV

  Eligibility

Ages Eligible for Study:   50 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Successful completion of study B2601001
  • MMSE 12 or greater

Exclusion Criteria:

  • Study B2601001 Week 32 MRI with clinically important exclusionary findings.
  • Experienced SAE, vasogenic edema and/or intracranial hemorrhage in study B2601001
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01369225

Locations
United States, Florida
MD Clinical
Hallandale Beach, Florida, United States, 33009
Munroe Regional Medical Center
Ocala, Florida, United States, 34471
Renstar Medical Research
Ocala, Florida, United States, 34471
Trinity Care Solutions
Ocala, Florida, United States, 34471
Advanced Imaging of Ocala
Ocala, Florida, United States, 34481
United States, Georgia
Atlanta Center for Medical Research
Atlanta, Georgia, United States, 30308
United States, Maryland
Foers Medical Arts Pharmacy
Bethesda, Maryland, United States, 20814
CBH Health, LLC
Rockville, Maryland, United States, 20850
United States, Michigan
Borgess Medical Center
Kalamazoo, Michigan, United States, 49048
Borgess Research Institute
Kalamazoo, Michigan, United States, 49048
KNI Southwest Michigan Imaging Center, LLC
Kalamazoo, Michigan, United States, 49048
United States, Missouri
Millennium Psychiatric Associates, LLC
Creve Coeur, Missouri, United States, 63141
DePaul Health Center-MRI Department
St. Louis, Missouri, United States, 63044
United States, New Jersey
Memory Enhancement Center of America, Inc.
Eatontown, New Jersey, United States, 07724
Central Jersey Radiology
Oakhurst, New Jersey, United States, 07755
Korea, Republic of
Seoul National University Hospital, Department Neurology
Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-707
Inha University Hospital, Department of Neurology
Incheon, Korea, Republic of, 400-711
Samsung Medical Center, Department of Neurology
Seoul, Korea, Republic of, 1350710
Korea University Anam Hospital IRB
Seoul, Korea, Republic of, 136-705
ASAN Medical Center
Seoul, Korea, Republic of, 138-736
Konkuk University Medical Center, Department of Neurology
Seoul, Korea, Republic of, 143914
Sponsors and Collaborators
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01369225     History of Changes
Other Study ID Numbers: B2601003
Study First Received: May 10, 2011
Results First Received: June 15, 2016
Last Updated: January 19, 2017

Keywords provided by Pfizer:
Randomized
Safety Study
Open Label

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on March 30, 2017